Drugs / Recombinant Humanized Type III Collagen
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06725082 | Dec 2024 → Dec 2025 overdue | breast cancer | Peking University People's Hospital | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07377734 | Jan 2026 → Dec 2027 expected | atypical endometrial hyperplasia, endometrial cancer | Wang Jianliu | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Humanized Type III Collagen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07377734 ↗ |
| Known as | rhCOL3 | “recombinant humanized Type III Collagen (rhCOL3)” NCT06725082 ↗ |
| Modality | Protein / enzyme biologic | “recombinant humanized Type III Collagen (rhCOL3)” NCT06725082 ↗ |
| Route | Other | “rhCOL3/saline will be injected around the tumor” NCT06725082 ↗ |